Incyte (NASDAQ: INCY)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-02 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.680 | 0.550 | -0.1300 | ||||
REV | 750.660M | 733.235M | -17.425M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.
Other companies in Incyte’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Incyte (NASDAQ: INCY) was reported by Morgan Stanley on Thursday, May 5, 2022. The analyst firm set a price target for 77.00 expecting INCY to rise to within 12 months (a possible 3.58% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Incyte (NASDAQ: INCY) is $74.34 last updated May 19, 2022, 8:00 PM UTC.
There are no upcoming dividends for Incyte.
Incyte’s Q2 earnings are confirmed for Tuesday, August 2, 2022.
There is no upcoming split for Incyte.
Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.